These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1961 related articles for article (PubMed ID: 32991844)

  • 1. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
    Piccoli L; Park YJ; Tortorici MA; Czudnochowski N; Walls AC; Beltramello M; Silacci-Fregni C; Pinto D; Rosen LE; Bowen JE; Acton OJ; Jaconi S; Guarino B; Minola A; Zatta F; Sprugasci N; Bassi J; Peter A; De Marco A; Nix JC; Mele F; Jovic S; Rodriguez BF; Gupta SV; Jin F; Piumatti G; Lo Presti G; Pellanda AF; Biggiogero M; Tarkowski M; Pizzuto MS; Cameroni E; Havenar-Daughton C; Smithey M; Hong D; Lepori V; Albanese E; Ceschi A; Bernasconi E; Elzi L; Ferrari P; Garzoni C; Riva A; Snell G; Sallusto F; Fink K; Virgin HW; Lanzavecchia A; Corti D; Veesler D
    Cell; 2020 Nov; 183(4):1024-1042.e21. PubMed ID: 32991844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.
    Iyer AS; Jones FK; Nodoushani A; Kelly M; Becker M; Slater D; Mills R; Teng E; Kamruzzaman M; Garcia-Beltran WF; Astudillo M; Yang D; Miller TE; Oliver E; Fischinger S; Atyeo C; Iafrate AJ; Calderwood SB; Lauer SA; Yu J; Li Z; Feldman J; Hauser BM; Caradonna TM; Branda JA; Turbett SE; LaRocque RC; Mellon G; Barouch DH; Schmidt AG; Azman AS; Alter G; Ryan ET; Harris JB; Charles RC
    Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33033172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
    Kreye J; Reincke SM; Kornau HC; Sánchez-Sendin E; Corman VM; Liu H; Yuan M; Wu NC; Zhu X; Lee CD; Trimpert J; Höltje M; Dietert K; Stöffler L; von Wardenburg N; van Hoof S; Homeyer MA; Hoffmann J; Abdelgawad A; Gruber AD; Bertzbach LD; Vladimirova D; Li LY; Barthel PC; Skriner K; Hocke AC; Hippenstiel S; Witzenrath M; Suttorp N; Kurth F; Franke C; Endres M; Schmitz D; Jeworowski LM; Richter A; Schmidt ML; Schwarz T; Müller MA; Drosten C; Wendisch D; Sander LE; Osterrieder N; Wilson IA; Prüss H
    Cell; 2020 Nov; 183(4):1058-1069.e19. PubMed ID: 33058755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.
    Tai W; Zhang X; He Y; Jiang S; Du L
    Antiviral Res; 2020 Jul; 179():104820. PubMed ID: 32405117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.
    Rogers TF; Zhao F; Huang D; Beutler N; Burns A; He WT; Limbo O; Smith C; Song G; Woehl J; Yang L; Abbott RK; Callaghan S; Garcia E; Hurtado J; Parren M; Peng L; Ramirez S; Ricketts J; Ricciardi MJ; Rawlings SA; Wu NC; Yuan M; Smith DM; Nemazee D; Teijaro JR; Voss JE; Wilson IA; Andrabi R; Briney B; Landais E; Sok D; Jardine JG; Burton DR
    Science; 2020 Aug; 369(6506):956-963. PubMed ID: 32540903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2.
    Yu F; Xiang R; Deng X; Wang L; Yu Z; Tian S; Liang R; Li Y; Ying T; Jiang S
    Signal Transduct Target Ther; 2020 Sep; 5(1):212. PubMed ID: 32963228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
    Hussain A; Hasan A; Nejadi Babadaei MM; Bloukh SH; Chowdhury MEH; Sharifi M; Haghighat S; Falahati M
    Biomed Pharmacother; 2020 Oct; 130():110559. PubMed ID: 32768882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
    Du S; Cao Y; Zhu Q; Yu P; Qi F; Wang G; Du X; Bao L; Deng W; Zhu H; Liu J; Nie J; Zheng Y; Liang H; Liu R; Gong S; Xu H; Yisimayi A; Lv Q; Wang B; He R; Han Y; Zhao W; Bai Y; Qu Y; Gao X; Ji C; Wang Q; Gao N; Huang W; Wang Y; Xie XS; Su XD; Xiao J; Qin C
    Cell; 2020 Nov; 183(4):1013-1023.e13. PubMed ID: 32970990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
    Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
    Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
    Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
    Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.
    Hanke L; Vidakovics Perez L; Sheward DJ; Das H; Schulte T; Moliner-Morro A; Corcoran M; Achour A; Karlsson Hedestam GB; Hällberg BM; Murrell B; McInerney GM
    Nat Commun; 2020 Sep; 11(1):4420. PubMed ID: 32887876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana.
    Rattanapisit K; Shanmugaraj B; Manopwisedjaroen S; Purwono PB; Siriwattananon K; Khorattanakulchai N; Hanittinan O; Boonyayothin W; Thitithanyanont A; Smith DR; Phoolcharoen W
    Sci Rep; 2020 Oct; 10(1):17698. PubMed ID: 33077899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
    Huo J; Le Bas A; Ruza RR; Duyvesteyn HME; Mikolajek H; Malinauskas T; Tan TK; Rijal P; Dumoux M; Ward PN; Ren J; Zhou D; Harrison PJ; Weckener M; Clare DK; Vogirala VK; Radecke J; Moynié L; Zhao Y; Gilbert-Jaramillo J; Knight ML; Tree JA; Buttigieg KR; Coombes N; Elmore MJ; Carroll MW; Carrique L; Shah PNM; James W; Townsend AR; Stuart DI; Owens RJ; Naismith JH
    Nat Struct Mol Biol; 2020 Sep; 27(9):846-854. PubMed ID: 32661423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
    Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
    Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.
    Barnes CO; West AP; Huey-Tubman KE; Hoffmann MAG; Sharaf NG; Hoffman PR; Koranda N; Gristick HB; Gaebler C; Muecksch F; Lorenzi JCC; Finkin S; Hägglöf T; Hurley A; Millard KG; Weisblum Y; Schmidt F; Hatziioannou T; Bieniasz PD; Caskey M; Robbiani DF; Nussenzweig MC; Bjorkman PJ
    Cell; 2020 Aug; 182(4):828-842.e16. PubMed ID: 32645326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
    Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
    Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 99.